Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.

ClinicalTrials.gov ID: NCT02487498

Public ClinicalTrials.gov record NCT02487498. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Randomized, Double-blind, Double-dummy, Active Controlled, Two-period Cross-over Study to Assess the Efficacy, Safety and Tolerability of Indacaterol Maleate/Glycopyrronium Bromide Compared to Umeclidinium Bromide/Vilanterol in COPD Patients With Moderate to Severe Airflow Limitation.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while maintaining an acceptable safety profile.

Study identification

NCT ID
NCT02487498
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
355 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 27, 2015 (Actual)
Primary completion
Sep 6, 2016 (Actual)
Completion
Sep 6, 2016 (Actual)
Last update posted
Apr 2, 2018

2015 – 2016

United States locations

U.S. sites
53
U.S. states
16
U.S. cities
48
Facility City State ZIP Site status
Novartis Investigative Site Anaheim California 92801 —
Novartis Investigative Site Escondido California 92025 —
Novartis Investigative Site Riverside California 92506 —
Novartis Investigative Site San Diego California 92103-8415 —
Novartis Investigative Site San Diego California 92117 —
Novartis Investigative Site San Diego California 92120 —
Novartis Investigative Site Chiefland Florida 32626 —
Novartis Investigative Site Clearwater Florida 33765 —
Novartis Investigative Site Gainesville Florida 32607 —
Novartis Investigative Site Miami Florida 33144 —
Novartis Investigative Site Miami Florida 33169 —
Novartis Investigative Site Winter Park Florida 32789 —
Novartis Investigative Site Florence Kentucky 41042 —
Novartis Investigative Site Owensboro Kentucky 42303 —
Novartis Investigative Site North Dartmouth Massachusetts 02747 —
Novartis Investigative Site Livonia Michigan 48152 —
Novartis Investigative Site Saint Charles Missouri 63301 —
Novartis Investigative Site St Louis Missouri 63141 —
Novartis Investigative Site Lincoln Nebraska 68510 —
Novartis Investigative Site Omaha Nebraska 68134 —
Novartis Investigative Site Skillman New Jersey 08558 —
Novartis Investigative Site Gastonia North Carolina 28054 —
Novartis Investigative Site Monroe North Carolina 28112 —
Novartis Investigative Site New Bern North Carolina 28562 —
Novartis Investigative Site Raleigh North Carolina 27607 —
Novartis Investigative Site Shelby North Carolina 28150 —
Novartis Investigative Site Wilmington North Carolina 28401 —
Novartis Investigative Site Cincinnati Ohio 45231 —
Novartis Investigative Site Cincinnati Ohio 45245 —
Novartis Investigative Site Eugene Oregon 97404 —
Novartis Investigative Site Pottstown Pennsylvania 19464 —
Novartis Investigative Site Anderson South Carolina 29621 —
Novartis Investigative Site Charleston South Carolina 29406-7108 —
Novartis Investigative Site Charleston South Carolina 29407 —
Novartis Investigative Site Easley South Carolina 29640 —
Novartis Investigative Site Fort Mill South Carolina 29707 —
Novartis Investigative Site Gaffney South Carolina 29340 —
Novartis Investigative Site Greenville South Carolina 29615 —
Novartis Investigative Site Mt. Pleasant South Carolina 29464 —
Novartis Investigative Site Rock Hill South Carolina 29732 —
Novartis Investigative Site Seneca South Carolina 29678 —
Novartis Investigative Site Simpsonville South Carolina 29681 —
Novartis Investigative Site Spartanburg South Carolina 29303 —
Novartis Investigative Site Union South Carolina 29379 —
Novartis Investigative Site Amarillo Texas 79106-4165 —
Novartis Investigative Site Boerne Texas 78006 —
Novartis Investigative Site El Paso Texas 79903 —
Novartis Investigative Site Fort Worth Texas 76104 —
Novartis Investigative Site Kingwood Texas 77339 —
Novartis Investigative Site Plano Texas 75093 —
Novartis Investigative Site San Antonio Texas 78299 —
Novartis Investigative Site Richmond Virginia 23225 —
Novartis Investigative Site Greenfield Wisconsin 53228 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02487498, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 2, 2018 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02487498 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →